Persistent URL of this record https://hdl.handle.net/1887/104682
In Collections
This item can be found in the following collections:
Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REC) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes
- All authors
- Demetri, G.D.; Jeffers, M.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Rutkowski, P.; Gelderblom, H.; Hohenberger, P.; Leahy, M.G.; Mehren, M. von; Joensuu, H.; Badalamenti, G.; Blackstein, M.E.; Cesne, A. le; Schoffski, P.; Maki, R.G.; Xu, J.M.; Nishida, T.; Kuss, I.; Casali, P.G.
- Date
- 2013-05-20
- Journal
- Journal of Clinical Oncology
- Volume
- 31
- Issue
- 15